| Year |
Citation |
Score |
| 2015 |
Cox JB, Cangelosi MJ, Ortendahl JD, Meckley LM, Bentley TG, Shriner K, Fox J. Cost-Effectiveness of Bronchial Thermoplasty in Patients with Poorly Controlled, Severe, Persistent Asthma Journal of Allergy and Clinical Immunology. 135: AB49. DOI: 10.1016/J.Jaci.2014.12.1089 |
0.311 |
|
| 2014 |
Montero AJ, Meckley LM, Anene AM, Bentley TGK, Ortendahl JD, Martinez JM. Cost-effectiveness of metal stents in pancreatic cancer. Journal of Clinical Oncology. 32: 260-260. DOI: 10.1200/Jco.2014.32.3_Suppl.260 |
0.312 |
|
| 2010 |
Giovanni MA, Fickie MR, Lehmann LS, Green RC, Meckley LM, Veenstra D, Murray MF. Health-care referrals from direct-to-consumer genetic testing. Genetic Testing and Molecular Biomarkers. 14: 817-9. PMID 20979566 DOI: 10.1089/Gtmb.2010.0051 |
0.493 |
|
| 2010 |
Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 28: 61-74. PMID 20014877 DOI: 10.2165/11318240-000000000-00000 |
0.517 |
|
| 2010 |
Meckley LM, Greenberg D, Cohen JT, Neumann PJ. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 30: 314-9. PMID 19773582 DOI: 10.1177/0272989X09344749 |
0.316 |
|
| 2008 |
Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thrombosis and Haemostasis. 100: 229-239. PMID 18690342 DOI: 10.1160/Th07-09-0552 |
0.497 |
|
| 2008 |
Garrison LP, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 40: 377-401. PMID 18464050 DOI: 10.1080/03602530801952500 |
0.446 |
|
| 2008 |
Meckley L, Gudgeon J, Anderson J, Williams M, Veenstra D. PHP72 GENETIC TESTING FOR WARFARIN INITIATION: A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE Value in Health. 11: A51. DOI: 10.1016/S1098-3015(10)70170-4 |
0.538 |
|
| 2007 |
Gudgeon J, Williams M, Anderson J, Meckley L, Veenstra D. PCASE10 SHOULD GENETIC TESTING BE USED TO GUIDE WARFARIN THERAPY? Value in Health. 10: A205-A206. DOI: 10.1016/S1098-3015(10)69150-4 |
0.508 |
|
| 2007 |
Meckley L, Austin M, Garrison L, Veenstra D. PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY Value in Health. 10: A53. DOI: 10.1016/S1098-3015(10)68698-6 |
0.549 |
|
| 2006 |
Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenetics and Genomics. 16: 139-47. PMID 16424826 DOI: 10.1097/01.Fpc.0000189801.96220.82 |
0.513 |
|
| 2005 |
Soon J, Meckley L, Levine M, Fielding D, Ensom M, Marciante K. Pihi9 Cost-Effectiveness Of Pharmacist Prescribing Authority For Emergency Contraception In British Columbia Value in Health. 8: 303. DOI: 10.1016/S1098-3015(10)62779-9 |
0.315 |
|
| 2004 |
Meckley L, Veenstra D. SC4 ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS Value in Health. 7: 228-229. DOI: 10.1016/S1098-3015(10)62093-1 |
0.485 |
|
| Show low-probability matches. |